Pipeline
StrideBio’s therapeutic programs (STRX) currently include potential in vivo treatments in development with key partners for Friedreich's Ataxia, Niemann-Pick Disease Type C (NPC), Angelman Syndrome, Dravet Syndrome and Rett Syndrome.
Partner
Discovery Pre-Clinical Clinical Commercial
STRX-110 Friedreich's Ataxia
STRX-210 Niemann Pick Disease Type C
STRX-220 Angelman Syndrome
STRX-230 Rett Syndrome
STRX-240 Dravet Syndrome
STRX-310 Undisclosed
STRX-320 Undisclosed

Patient and Family Resources

Here are a few of the many worthy organizations that provide resources and more information about Friedreich’s Ataxia, Niemann-Pick Disease Type C (NPC), Angelman Syndrome, Dravet Syndrome and Rett Syndrome. The links below are external sites maintained by the respective organizations who are solely responsible for content.

Friedreich’s Ataxia

Friedreich’s Ataxia Research Alliance (FARA)

Niemann-Pick Disease Type C (NPC)

National Niemann-Pick Disease FoundationAra Parseghian Medical Research Fund, University of Notre DameFirefly Fund

Angelman Syndrome

Angelman Syndrome FoundationFoundation for Angelman Syndrome Therapeutics

Dravet Syndrome

Dravet Syndrome Foundation

Rett Syndrome

Rett Syndrome Research TrustRettSyndome.org

General Information

National Organization for Rare Diseases

 

StrideBio is deeply motivated and committed to advancing potential treatments to address these serious and rare diseases and we appreciate your interest in our development programs. Patient and advocacy communities contribute greatly to our understanding of these diseases, and it is our desire to work closely with these groups as we advance our programs.